skip to main content



Catalogue No.


Cell Line Name


Cell Line Description

The MCF7/182R-6 Cell line is a breast cancer cell line resistant to fulvestrant. The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant.Oestrogen receptor only. Upon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells.

General Info



Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.



Oestrogen receptors only

Tissue of Origin



Polygonal epithelia

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D3S1358: 16
D5S818: 11,12
D7S820: 9
D8S1179: 10,14
D13S317: 11
D16S539: 11,12
D18S51: 14
D21S11: 30
FGA: 23,25
Penta D: 12
Penta E: 7,12
TH01: 6
TPOX: 9,12
vWA: 14,15



Culture Conditions

Cell Type


Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin or trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Culture Medium

Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance

Growth Mode


Additional Info


Cancer Research Technologies Limited (Ximbio)

Country of Origin


Hazard Group (ACDP)

Hazard Group (ACDP) 2



Thrane et al. 2014. Oncogene. PMID: 25362855. Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-13. PMID: 19697122. Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071. Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041. Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194. Nabha et al. 2005. Oncogene. 24(19):3166-76. PMID: 15735693.


Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/182R-6 (ECACC 16022506).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.